Ciprofloxacin-resistant campylobacteriosis in the UK

By contrast, the levels of erythromycin resistance have remained unchanged at under 2.5%. Since ciprofloxacin can no longer be safely assumed to be an effective treatment, routine laboratory suscept ibility testing of isolates is essential.

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2010-12, Vol.376 (9757), p.1987-1987
Main Authors: Cody, Alison J, Clarke, Lorraine, Bowler, Ian CJW, Dingle, Kate E
Format: Article
Language:English
Subjects:
Animals
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - pharmacology
Bacteria
Campylobacter - drug effects
Campylobacter - isolation & purification
Campylobacter Infections - drug therapy
Campylobacter Infections - epidemiology
Campylobacter Infections - prevention & control
Campylobacter Infections - veterinary
Ciprofloxacin - administration & dosage
Ciprofloxacin - pharmacology
Drug Resistance, Bacterial
Fluoroquinolones - administration & dosage
Humans
Incidence
Internal Medicine
Poultry
Poultry Diseases - prevention & control
United Kingdom - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:By contrast, the levels of erythromycin resistance have remained unchanged at under 2.5%. Since ciprofloxacin can no longer be safely assumed to be an effective treatment, routine laboratory suscept ibility testing of isolates is essential.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(10)62261-1